Use of Microdose Phenotyping to Individualise Dosing of Patients

Clinical Pharmacokinetics

Volumn 54, Issue 9, 2015, Pages 893-900

  Hohmann, Nicolas ^a   Haefeli, Walter E ^a   Mikus, Gerd ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; DRUG;

ARTICLE; CLINICAL MEDICINE; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; DRUG MICRODOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG USE; ENZYME ACTIVITY; FIRST IN HUMAN STUDY; HUMAN; INTRINSIC CLEARANCE; LIMIT OF QUANTITATION; MICRODOSE PHENOTYPING; NONHUMAN; PATIENT SAFETY; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ADVERSE DRUG REACTION; DOSE CALCULATION; DOSE RESPONSE; DRUG INTERACTION; DRUG MONITORING; PROCEDURES;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; DRUG INTERACTIONS; DRUG MONITORING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHENOTYPE; PRECISION MEDICINE;

EID: 84941188118     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-015-0278-y     Document Type: Article

References (37)

1. Shah RR, Smith RL. Addressing phenoconversion: the Achilles’ heel of personalized medicine. Br J Clin Pharmacol. 2015;79:222–40.
2. Donzelli M, Derungs A, Serratore MG, Noppen C, Nezic L, Krahenbuhl S, et al. The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots. Clin Pharmacokinet. 2014;53:271–82.
3. Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, et al. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the “Cooperstown 5 + 1 cocktail”. Clin Pharmacol Ther. 2003;74:437–47.
4. Doroshyenko O, Rokitta D, Zadoyan G, Klement S, Schlafke S, Dienel A, et al. Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome P450 enzymes in healthy volunteers. Drug Metab Dispos. 2013;41:987–93.
5. Ieiri I, Fukae M, Maeda K, Ando Y, Kimura M, Hirota T, et al. Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing. Int J Clin Pharmacol Ther. 2012;50:689–700.
6. Ieiri I, Doi Y, Maeda K, Sasaki T, Kimura M, Hirota T, et al. Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose. J Clin Pharmacol. 2012;52:1078–89.
7. Stenstrom K, Sydoff M, Mattsson S. Microdosing for early biokinetic studies in humans. Radiat Prot Dosimetry. 2010;139:348–52.
8. Maeda K, Sugiyama Y. Novel strategies for microdose studies using non-radiolabeled compounds. Adv Drug Deliv Rev. 2011;63:532–8.
9. Burhenne J, Halama B, Maurer M, Riedel KD, Hohmann N, Mikus G, et al. Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1′-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry. Anal Bioanal Chem. 2012;402:2439–50.
10. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry: analytical procedures and methods validation for drugs and biologics. 2014. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM386366.pdf. Accessed 27 Feb 2015.
11. Halama B, Hohmann N, Burhenne J, Weiss J, Mikus G, Haefeli WE. A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. Clin Pharmacol Ther. 2013;93:564–71.
12. Hohmann N, Kocheise F, Carls A, Burhenne J, Haefeli WE, Mikus G. Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. Br J Clin Pharmacol. 2015;79:278–85.
13. Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the “cocktail” approach. Clin Pharmacol Ther. 2007;81:270–83.
14. Birkett DJ. Pharmacokinetics made easy 9: non-linear pharmacokinetics. Aust Prescr. 1994;17:36–8.
15. Lappin G, Garner RC. The utility of microdosing over the past 5 years. Expert Opin Drug Metab Toxicol. 2008;4:1499–506.
16. Toutain PL, Bousquet-Melou A. Free drug fraction vs free drug concentration: a matter of frequent confusion. J Vet Pharmacol Ther. 2002;25:460–3.
17. Rowland M, Tozer T. Clinical pharmacokinetics and pharmacodynamics. 4th ed. Baltimore: Lippincott Williams & Wilkins, a Wolters Kluwer business; 2011.
18. European Medicines Agency (EMA). Summary of product characteristics: Optruma 60 mg. 2008. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000185/WC500048416.pdf. Accessed 9 Apr 2015.
19. Chatelut E, Puisset F. The scientific basis of body surface area-based dosing. Clin Pharmacol Ther. 2014;95:359–61.
20. Stoll F, Burhenne J, Lausecker B, Weiss J, Thomsen T, Haefeli WE, et al. Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity. J Clin Pharmacol. 2013;53:1199–204.
21. van der Bol JM, Mathijssen RH, Creemers GJ, Planting AS, Loos WJ, Wiemer EA, et al. A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin Cancer Res. 2010;16:736–42.
22. de Wit D, Gelderblom H, Sparreboom A, den Hartigh J, den Hollander M, Konig-Quartel JM, et al. Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer. Cancer Chemother Pharmacol. 2014;73:87–96.
23. Harvey RD, Morgan ET. Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents. Clin Pharmacol Ther. 2014;96:449–57.
24. Mooij MG, Schwarz UI, de Koning BA, Leeder JS, Gaedigk R, Samsom JN, et al. Ontogeny of human hepatic and intestinal transporter gene expression during childhood: age matters. Drug Metab Dispos. 2014;42:1268–74.
25. Kleiber N, Tromp K, Mooij MG, van de Vathorst S, Tibboel D, de Wildt SN. Ethics of drug research in the pediatric intensive care unit. Paediatr Drugs. 2015;17:43–53.
26. Gordi T, Baillie R, le Vuong T, Abidi S, Dueker S, Vasquez H, et al. Pharmacokinetic analysis of 14C-ursodiol in newborn infants using accelerator mass spectrometry. J Clin Pharmacol. 2014;54:1031–7.
27. Mooij MG, van Duijn E, Knibbe CA, Windhorst AD, Hendrikse NH, Vaes WH, et al. Pediatric microdose study of [(14)C]paracetamol to study drug metabolism using accelerated mass spectrometry: proof of concept. Clin Pharmacokinet. 2014;53:1045–51.
28. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendations. 2012. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf. Accessed 27 Feb 2015.
29. Markert C, Ngui P, Hellwig R, Wirsching T, Kastner IM, Riedel KD, et al. Influence of St. John’s wort on the steady-state pharmacokinetics and metabolism of bosentan. Int J Clin Pharmacol Ther. 2014;52:328–36.
30. Rasmussen-Torvik LJ, Stallings SC, Gordon AS, Almoguera B, Basford MA, Bielinski SJ, et al. Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clin Pharmacol Ther. 2014;96:482–9.
31. D’Empaire I, Guico-Pabia CJ, Preskorn SH. Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant? J Psych Pract. 2011;17:330–9.
32. Hohmann N, Halama B, Siller N, Mikus G, Haefeli WE. Response to “can CYP3A activity be evaluated for drug interaction using a nanogram dose of probe drug?”: evaluation of CYP3A activity with microdoses of midazolam. Clin Pharmacol Ther. 2014;95:490–1.
33. Shin KH, Choi MH, Lim KS, Yu KS, Jang IJ, Cho JY. Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. Clin Pharmacol Ther. 2013;94:601–9.
34. Palmer JL, Scott RJ, Gibson A, Dickins M, Pleasance S. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). Br J Clin Pharmacol. 2001;52:555–61.
35. Blakey GE, Lockton JA, Perrett J, Norwood P, Russell M, Aherne Z, et al. Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1. Br J Clin Pharmacol. 2004;57:162–9.
36. Katzenmaier S, Markert C, Riedel KD, Burhenne J, Haefeli WE, Mikus G. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy. Clin Pharmacol Ther. 2011;90:666–73.
37. Croft M, Keely B, Morris I, Tann L, Lappin G. Predicting drug candidate victims of drug-drug interactions, using microdosing. Clin Pharmacokinet. 2012;51:237–46.